← Back to Search

Other

Treatment for Endometrial Cancer (TAPER Trial)

N/A
Waitlist Available
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 3 years
Awards & highlights

TAPER Trial Summary

This trial showed that a low-cost, practical tool can reliably distinguish endometrial cancers by molecular features. This information can help clinicians determine the best treatment for each patient.

Eligible Conditions
  • Endometrial Cancer

TAPER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pelvic recurrence
Secondary outcome measures
Overall survival
Patient Decisional Conflict Scale
Recurrence free survival
+2 more

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,469 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently engaged in this medical investigation?

"Affirmative. According to clinicaltrials.gov, this research investigation is currently recruiting participants, having first been posted on the 14th of July 2020 with a most recent update occurring on the 1st of March 2022. 276 candidates must be recruited from one site."

Answered by AI

Are individuals being enlisted for this medical experimentation currently?

"According to data on clinicaltrials.gov, this study was initially posted in July 2020 and amended last March 2022; thus one can conclude that it is actively seeking participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer
Jessica McAlpine 2020. "Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04705649.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top